Sir, We would like to report the case of a patient who developed a muscular and cutaneous clinical picture consistent with dermatomyositis while taking lovastatin for hypercholesterolaemia.
Our patient was a 63-year-old woman who was started on lovastatin (HMG-CoA reductase inhibitor, 20 mg daily) in 1992. She took no other drug. Two years later she developed proximal muscle weakness affecting the hip and shoulder girdles over a period of five months, as well as proximal dysphagia. Cutaneous involvement accompanied muscle weakness. A rash with heliotropic colour and oedema affected her upper eyelids. Gottron's papules were found over the extensor surfaces of the elbows, knees and the hands. Nailfolds showed periungual erythema and telangiectatic changes. Creatinine kinase, adolase and lactate dehydrogenase were raised. Renal function was normal. The electromyogram showed decreased amplitude and duration of motor units potentials and fibrillations on muscle contraction (myopathic changes) in proximal muscles. Muscle and skin biopsies showed chronic inflammatory perivascular infiltrates and widespread destruction of muscle fibres with phagocytic reaction. Chronic inflammatory infiltration and vacuolar degenerative changes in the papillary dermis were found. Immunological laboratory data and investigation for an underlying neoplasm were negative. She was started on prednisone (1 mg/kg/day) with great improvement of the muscle weakness. One year after diagnosis the patient was free of symptoms and the rash had completely resolved.
A long list of drugs can cause myopathic changes (box), although the exact mechanisms by which they cause myopathy is uncertain. Some, such as penicillamine, hydralazine, and procainamide, are immune mediated. Others 
